Ziyad Al-Aly, MD
@zalaly
Followers
32K
Following
6K
Media
399
Statuses
3K
Physician-Scientist | TIME100 Health https://t.co/AXG4WotuRc Profile: https://t.co/ywweQn5DHA…
United States
Joined February 2009
My full testimony before the U.S. Senate Committee on Health, Education, Labor and Pensions Video here thanks to @luckytran 👇
"The burden of disease and disability from Long COVID is on par with the burden of cancer and heart disease. The best way to prevent Long COVID is to prevent COVID in the first place. There is no Long COVID without COVID." Brilliant testimony by @zalaly! #HELPLongCovid
142
1K
3K
Honored to speak at @Harvard’s Radcliffe Institute workshop on #LongCOVID. I am energized by our 2 days of brainstorming about the road ahead. The challenges are real, but I’m leaving hopeful. Millions living with Long Covid are counting on our progress—we must keep keep pushing
45
79
605
It gets wilder. One of the researchers who is helping design this new generation of addictive foods is on GLP-1!!!!!!!
19
121
1K
For decades, the junk food industry has deliberately engineered foods to be addictive. Ozempic and other GLP-1 drugs have helped people break free from this cycle. In response, the industry is now searching for ways to counteract the effects of these medications, aiming to design
133
1K
6K
GLP-1 drugs are revolutionizing the way we think about obesity. It is a chronic disease (like high blood pressure), and might actually be a form of food addiction. One reason these drugs are so effective in treating obesity could be that they address the underlying addiction. We
0
8
55
This thread is a great explainer of our paper on the benefits and risks GLP-1 drugs https://t.co/cJR8t1fs4A Thanks @fperrywilson for this informative thread.
nature.com
Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...
Every week, I see a new study talking about this or that effect of GLP-1 receptor agonists like #ozempic. FINALLY, we have a study evaluating all the outcomes (good and bad) in one dataset. There are some... surprises. 🧵
0
6
25
New Long Covid policy paper from Norway outlines knowledge gaps and lessons learnt for developing preparedness for future pandemics. Section 5 (pictured below) outlines their recommendations. Led by Sara Illman, PhD and colleagues. https://t.co/yi4UN2dAew
3
83
213
Alzheimer, addictions, dépression… les effets bénéfiques de l’Ozempic et des médicaments apparentés My Ozempic piece has been translated into French; thanks the amazing team at Conversation in Paris. @FR_Conversation
https://t.co/dgt96SmRzI
theconversation.com
Les médicaments GLP-1 sont efficaces pour traiter le diabète et l’obésité. Ils pourraient l’être aussi pour lutter contre de nombreuses autres affections. Néanmoins, des effets indésirables existent.
1
8
58
I talked to Dani Blum from @nytimes about the potential role of GLP-1 drugs on Alzheimer’s disease. They seem promising, but more data is needed for sure. https://t.co/eX2afPQdHb
nytimes.com
Could medications like Ozempic benefit the brain? Here’s what scientists are learning.
0
5
29
Thanks to @DKThomp for hosting me on his podcast. We talked about the GLP-1 and more. Details in this post below.
New ep: Are GLP-1s "the greatest medical breakthrough of the 21st century"? A new study of 2m Veterans Affairs patients with diabetes found GLP1 use was associated with a reduced risk of: - substance use disorders - psychotic disorders - Alzheimer's and dementia - clotting and
0
3
26
To the community: A ‘yes’ to supporting Long Covid research is better than a ‘no.’ We will hold him to it—and I stand ready to work with him if he’s serious about advancing research and care for those impacted by Long Covid.
24
13
152
I applaud @RobertKennedyJr commitment to prioritizing funding for Long Covid. We stand ready to work with you to address the needs of Americans impacted by Long Covid. Thanks to @SenToddYoung for raising this important question. https://t.co/F1VYcynWDj via @YouTube
79
83
525
🚨 ICYMI: Our latest study shows that the popular GLP-1 weight loss drugs (e.g. Ozempic) have broad health benefits — reducing risks of 42 health conditions. They are not without risks — increasing risks of of 19 health conditions. https://t.co/cJR8t1fZU8
nature.com
Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...
0
13
42
🚨 I dive into the benefits and risks of Ozempic and similar weight loss drugs in this article for @ConversationUS 💊 These drugs may lower the risk of 42 health conditions but aren’t without risks https://t.co/vmXIUAGjr8 Free PDF of original article
theconversation.com
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.
4
27
103
🚨 I dive into the benefits and risks of Ozempic and similar weight loss drugs in this article for @ConversationUS 💊 These drugs may lower the risk of 42 health conditions but aren’t without risks https://t.co/vmXIUAGjr8 Free PDF of original article
theconversation.com
Research shows that people who take these weight-loss medications may have a lower risk of dementia and numerous other health conditions.
4
27
103
🚨 New from my team: In a study of over 2 million people, we comprehensively mapped the benefits and risks of GLP-1 (weight loss drugs) across 175 health conditions. 📄 Free access to the full study: https://t.co/EECMIiX8nd 🧵 Explore the key findings:
1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 https://t.co/cJR8t1fZU8
7
31
150
1. What are the benefits and risks of GLP1? Our new study in @naturemedicine comprehensively maps all the benefits and risks of GLP-1 receptor agonists (GLP-1) (Ozempic, Wegovy, Mounjaro, Zepbound). By @Biostayan, Taeyoung Choi and me 🧵 https://t.co/cJR8t1fZU8
nature.com
Nature Medicine - An atlas of the associations between the use of GLP-1 receptor agonists (GLP-1RAs) and 175 health outcomes reports the effectiveness and risks of GLP-1RAs compared with other...
36
301
1K
Let me address this. We wrote the grant to do this project in 2018. It was funded in 2020. We deliberately delayed this to devote time and effort to addressing Covid and Long Covid. My team and I remain committed to working on LC, but we cannot default on our other commitments.
@zalaly @NatureMedicine @Biostayan I must admit, I'm disappointed the most trusted voice in Long COVID research has dedicated time to non-COVID study. There must be enough researchers around who can study GLP-1. Meanwhile, LC sufferers need solutions and most people are ignoring the risks of COVID reinfections.
24
34
526
I sat down with @danaparish to talk about this and more. https://t.co/3ArNmf4VGY
🚨 NEW PODCAST EPISODE: The GLP-1 Revolution: New Study Reveals Stunning Brain Benefits, Some Risks 🚨 Dr. Ziyad Al-Aly @zalaly on the Promise & Perils of the Hottest Drugs on Earth 🔥 In this episode of The Dana Parish Podcast, I sit down with one of TIME100’s most Influential
2
25
87